CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Sevoflurane

七氟烷 杂质对照品Sevoflurane Impurities

EP28 个杂质条目28 impurity entries

本页汇总 七氟烷 的 28 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 28 impurity reference standards of Sevoflurane with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 七氟烷(Sevoflurane)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDegradation products of different water content sevoflurane in carbon dioxide absorbents by gas chromatography-mass spectrometry analysis
    Chinese medical journal · 2011 · Li Y et al.  ·  PMID 21542967
  2. 杂质研究Impurity studiesSevoflurane formulation water content influences degradation by Lewis acids in vaporizers
    Anesthesia and analgesia · 2009 · Kharasch ED et al.  ·  PMID 19448204  ·  DOI
  3. 杂质研究Impurity studiesSevoflurane and isoflurane genotoxicity in kidney cells of mice
    Arhiv za higijenu rada i toksikologiju · 2017 · Brozović G et al.  ·  PMID 28976881  ·  DOI
  4. 分析方法Analytical MethodsA straightforward method for determination of the sevoflurane metabolite hexafluoroisopropanol in urinary occupational medical samples by headspace-gas chromatography mass spectrometry
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023 · Selke S et al.  ·  PMID 37984163  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisReinvestigation of the Two-step Synthesis of Sevoflurane
    Iranian journal of pharmaceutical research : IJPR · 2015 · Moghimi A et al.  ·  PMID 26330861

七氟烷 —— 原料药与杂质对照品Sevoflurane — drug substance & impurities

共 29 个条目(含原料药本体)29 items incl. the drug substance
Sevoflurane structure
EP原料药 APIAPI
七氟烷Sevoflurane
Sevoflurane
CAS No.28523-86-6
Chemical FormulaC4H3F7O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 1 (Sevoflurane EP Impurity A) structure
EPA
七氟烷杂质1 (七氟烷EP杂质A)Sevoflurane Impurity 1 (Sevoflurane EP Impurity A)
Sevoflurane Impurity 1 (Sevoflurane EP Impurity A)
CAS No.58109-34-5
Chemical FormulaC4H2F6O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 2 (Sevoflurane EP Impurity B) structure
EPB
七氟烷杂质2 (七氟烷EP杂质B)Sevoflurane Impurity 2 (Sevoflurane EP Impurity B)
Sevoflurane Impurity 2 (Sevoflurane EP Impurity B)
CAS No.13171-18-1
Chemical FormulaC4H4F6O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 3 (Sevoflurane EP Impurity C) structure
EPC
七氟烷杂质3 (七氟烷EP杂质C)Sevoflurane Impurity 3 (Sevoflurane EP Impurity C)
Sevoflurane Impurity 3 (Sevoflurane EP Impurity C)
CAS No.920-66-1
Chemical FormulaC3H2F6O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 4 (Sevoflurane Related Compound D) structure
4
七氟烷杂质4(七氟烷相关化合物D)Sevoflurane Impurity 4 (Sevoflurane Related Compound D)
Sevoflurane Impurity 4 (Sevoflurane Related Compound D)
CAS No.194039-81-1
Chemical FormulaC7H4F12O2
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 5 structure
5
七氟烷杂质5Sevoflurane Impurity 5
Sevoflurane Impurity 5
CAS No.58109-33-4
Chemical FormulaC5H6F6O2
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 6 structure
6
七氟烷杂质6Sevoflurane Impurity 6
Sevoflurane Impurity 6
CAS No.33034-42-3
Chemical FormulaC4HCl3F6O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 7 structure
7
七氟烷杂质7Sevoflurane Impurity 7
Sevoflurane Impurity 7
CAS No.162401-06-1
Chemical FormulaC7H2F14O2
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 8 structure
8
七氟烷杂质8Sevoflurane Impurity 8
Sevoflurane Impurity 8
CAS No.26103-07-1
Chemical FormulaC4H3ClF6O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 9 structure
9
七氟烷杂质9Sevoflurane Impurity 9
Sevoflurane Impurity 9
CAS No.32793-53-6
Chemical FormulaC4HCl2F7O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 10 structure
10
七氟烷杂质10Sevoflurane Impurity 10
Sevoflurane Impurity 10
CAS No.158076-92-7
Chemical FormulaC5H5F5O2
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 12 structure
12
七氟烷杂质12Sevoflurane Impurity 12
Sevoflurane Impurity 12
CAS No.79507-76-9
Chemical FormulaC6H2F12O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 13 structure
13
七氟烷杂质13Sevoflurane Impurity 13
Sevoflurane Impurity 13
CAS No.856766-70-6
Chemical FormulaC4H2F6O2
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 15 structure
15
七氟烷杂质15Sevoflurane Impurity 15
Sevoflurane Impurity 15
CAS No.374-01-6
Chemical FormulaC3H5F3O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 16 structure
16
七氟烷杂质16Sevoflurane Impurity 16
Sevoflurane Impurity 16
CAS No.2378-02-1
Chemical FormulaC4HF9O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 17 structure
17
七氟烷杂质17Sevoflurane Impurity 17
Sevoflurane Impurity 17
CAS No.428-59-1
Chemical FormulaC3F6O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 20 structure
20
七氟烷杂质20Sevoflurane Impurity 20
Sevoflurane Impurity 20
CAS No.431-71-0
Chemical FormulaC3HF5O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 22 structure
22
七氟烷杂质22Sevoflurane Impurity 22
Sevoflurane Impurity 22
CAS No.13252-13-6
Chemical FormulaC6HF11O3
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 32 structure
32
七氟烷杂质32Sevoflurane Impurity 32
Sevoflurane Impurity 32
CAS No.1100832-66-3
Chemical FormulaC9H6ClF6NO
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 35 structure
35
七氟烷杂质35Sevoflurane Impurity 35
Sevoflurane Impurity 35
CAS No.354-58-5
Chemical FormulaC2Cl3F3
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 36 structure
36
七氟烷杂质36Sevoflurane Impurity 36
Sevoflurane Impurity 36
CAS No.333-36-8
Chemical FormulaC4H4F6O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 37 structure
37
七氟烷杂质37Sevoflurane Impurity 37
Sevoflurane Impurity 37
CAS No.15242-17-8
Chemical FormulaC6H5F7O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 38 structure
38
七氟烷杂质38Sevoflurane Impurity 38
Sevoflurane Impurity 38
CAS No.376-90-9
Chemical FormulaC5H6F6O2
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 39 structure
39
七氟烷杂质39Sevoflurane Impurity 39
Sevoflurane Impurity 39
CAS No.1027885-56-8
Chemical FormulaC5H2ClF9O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 40 structure
40
七氟烷杂质40Sevoflurane Impurity 40
Sevoflurane Impurity 40
CAS No.3082894-74-1
Chemical FormulaC5H2F10O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 41 structure
41
七氟烷杂质41Sevoflurane Impurity 41
Sevoflurane Impurity 41
CAS No.28523-85-5
Chemical FormulaC4H2Cl2F6O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 44 (Methoxyflurane) structure
44
七氟烷杂质44 (甲氧氟烷)Sevoflurane Impurity 44 (Methoxyflurane)
Sevoflurane Impurity 44 (Methoxyflurane)
CAS No.76-38-0
Chemical FormulaC3H4Cl2F2O
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 45 structure
45
七氟烷杂质45Sevoflurane Impurity 45
Sevoflurane Impurity 45
CAS No.194039-91-3
Chemical FormulaC5H5F7O2
Purity>95%询价On request
10mg25mg50mg100mg
Sevoflurane Impurity 46 structure
46
七氟烷杂质46Sevoflurane Impurity 46
Sevoflurane Impurity 46
CAS No.39492-90-5
Chemical FormulaC6HF11O6
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

七氟烷 —— 研究文献与合成路线Sevoflurane — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 七氟烷 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Sevoflurane. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Hypervolemia does not cause degradation of the endothelial glycocalyx layer during open hysterectomy performed under sevoflurane or propofol anesthesia
    Nemme J, Krizhanovskii C, Ntika S, et al. · Acta anaesthesiologica Scandinavica · 2020 · 被引 19cited 19
  2. Sevoflurane formulation water content influences degradation by Lewis acids in vaporizers
    Kharasch ED, Subbarao GN, Cromack KR, et al. · Anesthesia and analgesia · 2009 · 被引 10cited 10
  3. Lack of degradation of sevoflurane by a new carbon dioxide absorbent in humans
    Mchaourab A, Arain SR, Ebert TJ · Anesthesiology · 2001 · 被引 11cited 11
  4. Sevoflurane suppresses colorectal cancer malignancy by modulating β-catenin ubiquitination degradation via circSKA3
    Song W, Miao L, Zhang K, et al. · Cellular signalling · 2024 · 被引 4cited 4
  5. PLCG1 promotes sevoflurane-induced neuronal ferroptosis by enhancing K63-linked ubiquitination and proteasomal degradation of LAMP2A
    Chen J, Cai Y, Wang J, et al. · Experimental brain research · 2026
  6. Temperature as the primary risk factor for sevoflurane degradation: Identification and toxicological risk assessment of novel degradants by nuclear magnetic resonance (NMR) spectroscopy
    Jin Y, Li Y, Yang H, et al. · Journal of pharmaceutical and biomedical analysis · 2026

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE MANUFACTURE OF SEVOFLURANE
    BRAUN MAX · 公开号 WO2011018466WO2011018466 · 2011
  2. Method for the preparation of sevoflurane
    TERRELL ROSS C, LEVINSON JOSHUA A, YOUNG CHARLES W · 公开号 US2012022296US2012022296 · 2012
  3. Process for synthesizing Sevoflurane
    ZHIQUAN ZHAO · 公开号 CN101314560CN101314560 · 2008
  4. METHOD OF SYNTHESIZING SEVOFLURANE
    ZHAO ZHIQUAN · 公开号 WO2010000136WO2010000136 · 2010
  5. METHOD OF SYNTHESIZING SEVOFLURANE
    ZHAO ZHIQUAN · 公开号 EP2308819EP2308819 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

七氟烷 杂质谱研究要点Sevoflurane — impurity profiling notes

下面这些是拿到 七氟烷 的 29 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 29 impurity entries for Sevoflurane, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances